Mostrar el registro sencillo del ítem
Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
dc.creator | Kontopoulou K., Ainatzoglou A., Nakas C.T., Ifantidou A., Goudi G., Antoniadou E., Adamopoulos V., Papadopoulos N., Papazisis G. | en |
dc.date.accessioned | 2023-01-31T08:44:06Z | |
dc.date.available | 2023-01-31T08:44:06Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.vaccine.2021.07.065 | |
dc.identifier.issn | 0264410X | |
dc.identifier.uri | http://hdl.handle.net/11615/75093 | |
dc.description.abstract | This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive. © 2021 Elsevier Ltd | en |
dc.language.iso | en | en |
dc.source | Vaccine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111607466&doi=10.1016%2fj.vaccine.2021.07.065&partnerID=40&md5=71de1726c8c7af4c8d5158b1d8f8ee6a | |
dc.subject | comirnaty | en |
dc.subject | immunoglobulin G | en |
dc.subject | bnt 162 vaccine | en |
dc.subject | messenger RNA | en |
dc.subject | virus antibody | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | aging | en |
dc.subject | Article | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | drug efficacy | en |
dc.subject | female | en |
dc.subject | Greek (citizen) | en |
dc.subject | health care personnel | en |
dc.subject | human | en |
dc.subject | immunogenicity | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | medical history | en |
dc.subject | receptor binding | en |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
dc.subject | middle aged | en |
dc.subject | Antibodies, Viral | en |
dc.subject | COVID-19 | en |
dc.subject | COVID-19 Vaccines | en |
dc.subject | Humans | en |
dc.subject | Middle Aged | en |
dc.subject | RNA, Messenger | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Elsevier Ltd | en |
dc.title | Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |